Sensorineural Hearing Loss Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sensorineural Hearing Loss pipeline constitutes 20+ key companies continuously working towards developing 21+ Sensorineural Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Sensorineural Hearing Loss Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sensorineural Hearing Loss Market.

The Sensorineural Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sensorineural Hearing Loss Pipeline Report: https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Sensorineural Hearing Loss treatment therapies with a considerable amount of success over the years.
• Sensorineural Hearing Loss companies working in the treatment market are Audion Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Sensorineural Hearing Loss treatment
• Emerging Sensorineural Hearing Loss therapies in the different phases of clinical trials are- LY 3056480, ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Sensorineural Hearing Loss market in the coming years.
• In December 2025, Med-El USA announced that the U.S. Food and Drug Administration (FDA) has granted approval to expand the indication for its cochlear implants to include children aged seven months and older with bilateral sensorineural hearing loss (SNHL). With this decision, Med-El's cochlear implant system becomes the only FDA-approved option available for infants in this age group, enabling earlier exposure to sound and supporting timely speech and language development.
• In December 2025, Seattle-based Sound Pharmaceuticals (SPI) announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation (BTD) to its investigational therapy SPI-1005 for the treatment of hearing loss in patients with Ménière's disease (MD). MD is a complex inner-ear disorder characterized by low- to mid-frequency hearing loss, tinnitus, vertigo, and dizziness, and currently lacks any FDA-approved pharmacologic treatments. This designation represents the first time BTD has been granted for MD. SPI-1005, an oral anti-inflammatory agent, is also the first therapy to receive Breakthrough Therapy Designation for sensorineural hearing loss, the most common form of hearing impairment linked to aging and dysfunction of the peripheral and central nervous systems.
• In July 2025, Rinri Therapeutics, a spinout from the University of Sheffield specializing in regenerative cell therapies for sensorineural hearing loss (SNHL), gained regulatory approval to begin its first-in-human clinical trial. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) authorized Rincell-1, an innovative otic neural progenitor cell therapy, for a Phase I/IIa study. Early clinical proof-of-concept results are expected within 12 months of the trial's start.
• In February 2025, SPI-1005 was an investigational drug featuring ebselen, a novel seleno-organic compound. Ebselen functions by mimicking and stimulating glutathione peroxidase (GPx) activity, helping reduce neuroinflammation in both the central and peripheral nervous systems. GPx plays a vital role in protecting various tissues, including those in the inner ear, retina, brain's prefrontal cortex, lungs, and kidneys. Its activity often declines due to aging or environmental damage. Research in multiple animal models has linked reduced GPx activity to the development of sensorineural hearing loss.
• In January 2025, US-based dermatology biopharma Eirion Therapeutics announced encouraging results from its first-in-human, double-blind, placebo-controlled trial of a topical therapy for age-related hair loss, showing a six-fold improvement in hair count compared to placebo. ET-02, the company's lead candidate for androgenic alopecia, was tested in 24 male participants across three US sites, successfully achieving its primary safety and tolerability goals. The company is also developing a preclinical oral version of ET-02, strengthening its pipeline of hair loss treatments.

Sensorineural Hearing Loss Overview
Sensorineural Hearing Loss (SNHL) is a type of permanent hearing loss caused by damage to the inner ear (cochlea) or the auditory nerve that carries sound signals to the brain. It is the most common form of hearing loss and can result from aging, prolonged noise exposure, genetic factors, infections, or certain medications. SNHL affects sound clarity and speech understanding, making it difficult to hear faint sounds or distinguish words in noisy environments. Unlike conductive hearing loss, it usually cannot be corrected with surgery but can be managed with hearing aids, cochlear implants, or emerging regenerative therapies.

Get a Free Sample PDF Report to know more about Sensorineural Hearing Loss Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Sensorineural Hearing Loss Drugs Under Different Phases of Clinical Development Include:
• LY 3056480: Audion Therapeutics
• ACOU085: Acousia Therapeutics
• Cochlear Hair Cell Regeneration: Decibel Therapeutics
• HY01: Suzhou Pharmaceutical Technology Co.,Ltd
• AC102: AudioCure Pharma GmbH
• SENS-401: Sensorion

Sensorineural Hearing Loss Route of Administration
Sensorineural Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Sensorineural Hearing Loss Molecule Type
Sensorineural Hearing Loss Products have been categorized under various Molecule types, such as
• Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Sensorineural Hearing Loss Pipeline Therapeutics Assessment
• Sensorineural Hearing Loss Assessment by Product Type
• Sensorineural Hearing Loss By Stage and Product Type
• Sensorineural Hearing Loss Assessment by Route of Administration
• Sensorineural Hearing Loss By Stage and Route of Administration
• Sensorineural Hearing Loss Assessment by Molecule Type
• Sensorineural Hearing Loss by Stage and Molecule Type

DelveInsight's Sensorineural Hearing Loss Report covers around 21+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sensorineural Hearing Loss product details are provided in the report. Download the Sensorineural Hearing Loss pipeline report to learn more about the emerging Sensorineural Hearing Loss therapies
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Sensorineural Hearing Loss Therapeutics Market include:
Key companies developing therapies for Sensorineural Hearing Loss are - Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

Sensorineural Hearing Loss Pipeline Analysis:
The Sensorineural Hearing Loss pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sensorineural Hearing Loss with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sensorineural Hearing Loss Treatment.
• Sensorineural Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sensorineural Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sensorineural Hearing Loss market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sensorineural Hearing Loss drugs and therapies
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sensorineural Hearing Loss Pipeline Market Drivers
• Rise in the Incidence of Sensorineural hearing loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Sensorineural Hearing Loss Market.

Sensorineural Hearing Loss Pipeline Market Barriers
• However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Sensorineural Hearing Loss Market growth.

Scope of Sensorineural Hearing Loss Pipeline Drug Insight
• Coverage: Global
• Key Sensorineural Hearing Loss Companies: Audion Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others
• Key Sensorineural Hearing Loss Therapies: LY 3056480, ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others
• Sensorineural Hearing Loss Therapeutic Assessment: Sensorineural Hearing Loss current marketed and Sensorineural Hearing Loss emerging therapies
• Sensorineural Hearing Loss Market Dynamics: Sensorineural Hearing Loss market drivers and Sensorineural Hearing Loss market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.